Search

Your search keyword '"Vose, Julie M."' showing total 824 results
Start Over Author "Vose, Julie M." Publication Type Academic Journals

Refine your results

more »

more »

more »

more »
824 results on '"Vose, Julie M."'

1. Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids

Author

Oluwole, Olalekan O., Forcade, Edouard, Muñoz, Javier, de Guibert, Sophie, Vose, Julie M., Bartlett, Nancy L., Lin, Yi, Deol, Abhinav, McSweeney, Peter, Goy, Andre H., Kersten, Marie José, Jacobson, Caron A., Farooq, Umar, Minnema, Monique C., Thieblemont, Catherine, Timmerman, John M., Stiff, Patrick, Avivi, Irit, Tzachanis, Dimitrios, Zheng, Yan, Vardhanabhuti, Saran, Nater, Jenny, Shen, Rhine R., Miao, Harry, Kim, Jenny J., and van Meerten, Tom

Published
2024
Full Text
View/download PDF

2. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study

Author

Linton, Kim M, Vitolo, Umberto, Jurczak, Wojciech, Lugtenburg, Pieternella J, Gyan, Emmanuel, Sureda, Anna, Christensen, Jacob Haaber, Hess, Brian, Tilly, Hervé, Cordoba, Raul, Lewis, David John, Okada, Craig, Hutchings, Martin, Clausen, Michael Roost, Sancho, Juan-Manuel, Cochrane, Tara, Leppä, Sirpa, Chamuleau, Martine E D, Gernhardt, Diana, Altıntaş, Işıl, Liu, Yan, Ahmadi, Tahamtan, Dinh, Minh H, Hoehn, Daniela, Favaro, Elena, Elliott, Brian, Thieblemont, Catherine, and Vose, Julie M

Published
2024
Full Text
View/download PDF

4. Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium

Author

Vose, Julie M., Fu, Kai, Wang, Lu, Mansoor, Adnan, Stewart, Douglas, Cheng, Hongxia, Smith, Lynette, Yuan, Ji, Qureishi, Hina Naushad, Link, Brian K., Cessna, Melissa H., Barr, Paul M., Kahl, Brad S., Mckinney, Matthew S., Khan, Nadia, Advani, Ranjana H., Martin, Peter, Goy, Andre H., Phillips, Tycel J., Mehta, Amitkumar, Kamdar, Manali, Crump, Michael, Pro, Barbara, Flowers, Christopher R., Jacobson, Caron A., Smith, Sonali M., Stephens, Deborah M., Bachanova, Veronika, Jin, Zhaohui, Wu, Shishou, Hernandez-Ilizaliturri, Francisco, Torka, Pallawi, Anampa-Guzmán, Andrea, Kashef, Farshid, Li, Xing, Sharma, Sunandini, Greiner, Timothy C., Armitage, James O., Lunning, Matthew, Weisenburger, Dennis D., Bociek, Robert G., Iqbal, Javeed, Yu, Guohua, and Bi, Chengfeng

Published
2023
Full Text
View/download PDF

5. Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium

Author

Jain, Michael D., Jacobs, Miriam T., Gao, Feng, Nastoupil, Loretta J., Spiegel, Jay Y., Lin, Yi, Dahiya, Saurabh, Lunning, Matthew, Lekakis, Lazaros, Reagan, Patrick, Oluwole, Olalekan, McGuirk, Joseph, Deol, Abhinav, Sehgal, Alison R., Goy, Andre, Hill, Brian T., Andreadis, Charalambos, Munoz, Javier, Chavez, Julio C, Bennani, N. Nora, Rapoport, Aaron P., Vose, Julie M., Miklos, David, Neelapu, Sattva S., Locke, Frederick L., and Ghobadi, Armin

Published
2024
Full Text
View/download PDF

6. High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series

Author

Epperla, Narendranath, Zayac, Adam S., Landsburg, Daniel J., Bock, Allison M., Nowakowski, Grzegorz S., Ayers, Emily C., Girton, Mark, Hu, Marie, Beckman, Amy, Li, Shaoying, Medeiros, L. Jeffrey, Chang, Julie E., Kurt, Habibe, Sandoval-Sus, Jose, Ansari-Lari, Mohammad Ali, Kothari, Shalin K., Kress, Anna, Xu, Mina L., Torka, Pallawi, Sundaram, Suchitra, Smith, Stephen D., Naresh, Kikkeri N., Karimi, Yasmin, Bond, David A., Evens, Andrew M., Naik, Seema G., Kamdar, Manali, Haverkos, Bradley M., Karmali, Reem, Farooq, Umar, Vose, Julie M., Rubinstein, Paul, Chaudhry, Amina, and Olszewski, Adam J.

Published
2024
Full Text
View/download PDF

7. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma

Author

Oluwole, Olalekan O, Bouabdallah, Krimo, Muñoz, Javier, De Guibert, Sophie, Vose, Julie M, Bartlett, Nancy L, Lin, Yi, Deol, Abhinav, McSweeney, Peter A, Goy, Andre H, Kersten, Marie José, Jacobson, Caron A, Farooq, Umar, Minnema, Monique C, Thieblemont, Catherine, Timmerman, John M, Stiff, Patrick, Avivi, Irit, Tzachanis, Dimitrios, Kim, Jenny J, Bashir, Zahid, McLeroy, Jeff, Zheng, Yan, Rossi, John M, Johnson, Lisa, Goyal, Lovely, and Meerten, Tom

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Lymphoma, Rare Diseases, Cancer, Hematology, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adrenal Cortex Hormones, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Immunological, Biological Products, Cytokine Release Syndrome, Dexamethasone, Female, Humans, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse, Male, Middle Aged, large B-cell lymphoma, axi-cel, chimaeric antigen receptor-T cell, prophylaxis, corticosteroids, cytokine release syndrome, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

ZUMA-1 (NCT02348216) examined the safety and efficacy of axicabtagene ciloleucel (axi-cel), an autologous CD19-directed chimaeric antigen receptor (CAR)-T cell therapy, in refractory large B-cell lymphoma. To reduce treatment-related toxicity, several exploratory safety management cohorts were added to ZUMA-1. Specifically, cohort 6 investigated management of cytokine release syndrome (CRS) and neurologic events (NEs) with prophylactic corticosteroids and earlier corticosteroid and tocilizumab intervention. CRS and NE incidence and severity were primary end-points. Following leukapheresis, patients could receive optional bridging therapy per investigator discretion. All patients received conditioning chemotherapy (days -5 through -3), 2 × 106  CAR-T cells/kg (day 0) and once-daily oral dexamethasone [10 mg, day 0 (before axi-cel) through day 2]. Forty patients received axi-cel. CRS occurred in 80% of patients (all grade ≤2). Any grade and grade 3 or higher NEs occurred in 58% and 13% of patients respectively. Sixty-eight per cent of patients did not experience CRS or NEs within 72 h of axi-cel. With a median follow-up of 8·9 months, objective and complete response rates were 95% and 80% respectively. Overall, prophylactic corticosteroids and earlier corticosteroid and/or tocilizumab intervention resulted in no grade 3 or higher CRS, a low rate of grade 3 or higher NEs and high response rates in this study population.

Published
2021

8. Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma

Author

Gerson, James N., Handorf, Elizabeth, Villa, Diego, Gerrie, Alina S., Chapani, Parv, Li, Shaoying, Medeiros, L. Jeffrey, Wang, Michael, Cohen, Jonathon B., Churnetski, Michael, Hill, Brian T., Sawalha, Yazeed, Hernandez-Ilizaliturri, Francisco J., Kothari, Shalin, Vose, Julie M., Bast, Martin, Fenske, Timothy, Rao Gari, Swapna Narayana, Maddocks, Kami J., Bond, David, Bachanova, Veronika, Kolla, Bhaskar, Chavez, Julio, Shah, Bijal, Lansigan, Frederick, Burns, Timothy, Donovan, Alexandra M., Wagner-Johnston, Nina, Messmer, Marcus, Mehta, Amitkumar, Anderson, Jennifer K., Reddy, Nishitha, Kovach, Alexandra E., Landsburg, Daniel J., Glenn, Martha, Inwards, David J., Ristow, Kay, Karmali, Reem, Kaplan, Jason B., Caimi, Paolo F., Rajguru, Saurabh, Evens, Andrew, Klein, Andreas, Umyarova, Elvira, Pulluri, Bhargavi, Amengual, Jennifer E., Lue, Jennifer K., Diefenbach, Catherine, Fisher, Richard I., and Barta, Stefan K.

Published
2023
Full Text
View/download PDF

9. High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study

Author

Zayac, Adam S., Landsburg, Daniel J., Hughes, Mitchell E., Bock, Allison M., Nowakowski, Grzegorz S., Ayers, Emily C., Girton, Mark, Hu, Marie, Beckman, Amy K., Li, Shaoying, Medeiros, L. Jeffrey, Chang, Julie E., Stepanovic, Adam, Kurt, Habibe, Sandoval-Sus, Jose, Ansari-Lari, M. Ali, Kothari, Shalin K., Kress, Anna, Xu, Mina L., Torka, Pallawi, Sundaram, Suchitra, Smith, Stephen D., Naresh, Kikkeri N., Karimi, Yasmin H., Epperla, Narendranath, Bond, David A., Farooq, Umar, Saad, Mahak, Evens, Andrew M., Pandya, Karan, Naik, Seema G., Kamdar, Manali, Haverkos, Bradley, Karmali, Reem, Oh, Timothy S., Vose, Julie M., Nutsch, Heather, Rubinstein, Paul G., Chaudhry, Amina, and Olszewski, Adam J.

Published
2023
Full Text
View/download PDF

10. Benchmarks for Academic Oncology Faculty.

Author

Anthony, Lowell, Atweh, George, Bhatia, Ravi, Carey, Lisa A, Chang, Jenny C, Edelman, Martin J, Kantoff, Philip W, Markham, Merry Jennifer, Messersmith, Wells, Nelson, Edward L, Oettel, Kurt, O'Regan, Ruth, Verschraegen, Claire F, and Vose, Julie M

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, 6.9 Resources and infrastructure (treatment evaluation), Evaluation of treatments and therapeutic interventions, Benchmarking, Faculty, Medical, Humans, Leadership, Medical Oncology, Research Personnel, Oncology and carcinogenesis
Abstract

The role of clinical researchers is vital to cancer progress. The teaching, research, and leadership roles that academic oncologists hold need to be accounted for and appropriately compensated. National metrics are currently inexistent, but are necessary to move the oncology research field forward. Clinical research and routine clinical care must be harmoniously integrated without competing. This article reviews the national landscape of clinical cancer research and proposes a call for action.

Published
2021

11. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.

Author

Nastoupil, Loretta J, Jain, Michael D, Feng, Lei, Spiegel, Jay Y, Ghobadi, Armin, Lin, Yi, Dahiya, Saurabh, Lunning, Matthew, Lekakis, Lazaros, Reagan, Patrick, Oluwole, Olalekan, McGuirk, Joseph, Deol, Abhinav, Sehgal, Alison R, Goy, Andre, Hill, Brian T, Vu, Khoan, Andreadis, Charalambos, Munoz, Javier, Westin, Jason, Chavez, Julio C, Cashen, Amanda, Bennani, N Nora, Rapoport, Aaron P, Vose, Julie M, Miklos, David B, Neelapu, Sattva S, and Locke, Frederick L

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Cancer, Clinical Research, Clinical Trials and Supportive Activities, Lymphoma, Hematology, Good Health and Well Being, Adult, Aged, Aged, 80 and over, Antigens, CD19, Biological Products, Clinical Trials, Phase II as Topic, Comorbidity, Cytokine Release Syndrome, Female, Humans, Immunotherapy, Adoptive, L-Lactate Dehydrogenase, Leukapheresis, Lymphoma, Large B-Cell, Diffuse, Male, Middle Aged, Organizational Policy, Patient Selection, Progression-Free Survival, Recurrence, Retrospective Studies, Severity of Illness Index, Standard of Care, Survival Rate, Young Adult, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeAxicabtagene ciloleucel (axi-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory large B-cell lymphoma (LBCL) on the basis of the single-arm phase II ZUMA-1 trial, which showed best overall and complete response rates in infused patients of 83% and 58%, respectively. We report clinical outcomes with axi-cel in the standard-of-care (SOC) setting for the approved indication.Patients and methodsData were collected retrospectively from all patients with relapsed/refractory LBCL who underwent leukapheresis as of September 30, 2018, at 17 US institutions with the intent to receive SOC axi-cel. Toxicities were graded and managed according to each institution's guidelines. Responses were assessed as per Lugano 2014 classification.ResultsOf 298 patients who underwent leukapheresis, 275 (92%) received axi-cel therapy. Compared with the registrational ZUMA-1 trial, 129 patients (43%) in this SOC study would not have met ZUMA-1 eligibility criteria because of comorbidities at the time of leukapheresis. Among the axi-cel-treated patients, grade ≥ 3 cytokine release syndrome and neurotoxicity occurred in 7% and 31%, respectively. Nonrelapse mortality was 4.4%. Best overall and complete response rates in infused patients were 82% (95% CI, 77% to 86%) and 64% (95% CI, 58% to 69%), respectively. At a median follow-up of 12.9 months from the time of CAR T-cell infusion, median progression-free survival was 8.3 months (95% CI, 6.0 to15.1 months), and median overall survival was not reached. Patients with poor Eastern Cooperative Oncology Group performance status of 2-4 and elevated lactate dehydrogenase had shorter progression-free and overall survival on univariable and multivariable analysis.ConclusionThe safety and efficacy of axi-cel in the SOC setting in patients with relapsed/refractory LBCL was comparable to the registrational ZUMA-1 trial.

Published
2020

12. Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

Author

Jacobs, Miriam T., Jain, Michael D., Gao, Feng, Nastoupil, Loretta J., Spiegel, Jay Y., Lin, Yi, Dahiya, Saurabh, Lunning, Matthew, Lekakis, Lazaros, Reagan, Patrick M., Oluwole, Olalekan O., McGuirk, Joseph, Deol, Abhinav, Sehgal, Alison, Goy, Andre, Hill, Brian T., Andreadis, Charalambos, Munoz, Javier, Chavez, Julio C., Bennani, N. Nora, Rapoport, Aaron P., Vose, Julie M., Miklos, David B., Neelapu, Sattva S., Ghobadi, Armin, and Locke, Frederick L.

Published
2022
Full Text
View/download PDF

13. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Author

Campo, Elias, Jaffe, Elaine S., Cook, James R., Quintanilla-Martinez, Leticia, Swerdlow, Steven H., Anderson, Kenneth C., Brousset, Pierre, Cerroni, Lorenzo, de Leval, Laurence, Dirnhofer, Stefan, Dogan, Ahmet, Feldman, Andrew L., Fend, Falko, Friedberg, Jonathan W., Gaulard, Philippe, Ghia, Paolo, Horwitz, Steven M., King, Rebecca L., Salles, Gilles, San-Miguel, Jesus, Seymour, John F., Treon, Steven P., Vose, Julie M., Zucca, Emanuele, Advani, Ranjana, Ansell, Stephen, Au, Wing-Yan, Barrionuevo, Carlos, Bergsagel, Leif, Chan, Wing C., Cohen, Jeffrey I., d'Amore, Francesco, Davies, Andrew, Falini, Brunangelo, Ghobrial, Irene M., Goodlad, John R., Gribben, John G., Hsi, Eric D., Kahl, Brad S., Kim, Won-Seog, Kumar, Shaji, LaCasce, Ann S., Laurent, Camille, Lenz, Georg, Leonard, John P., Link, Michael P., Lopez-Guillermo, Armando, Mateos, Maria Victoria, Macintyre, Elizabeth, Melnick, Ari M., Morschhauser, Franck, Nakamura, Shigeo, Narbaitz, Marina, Pavlovsky, Astrid, Pileri, Stefano A., Piris, Miguel, Pro, Barbara, Rajkumar, Vincent, Rosen, Steven T., Sander, Birgitta, Sehn, Laurie, Shipp, Margaret A., Smith, Sonali M., Staudt, Louis M., Thieblemont, Catherine, Tousseyn, Thomas, Wilson, Wyndham H., Yoshino, Tadashi, Zinzani, Pier-Luigi, Dreyling, Martin, Scott, David W., Winter, Jane N., and Zelenetz, Andrew D.

Published
2022
Full Text
View/download PDF

16. ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project

Author

Shustov, Andrei, Cabrera, Maria Elena, Civallero, Monica, Bellei, Monica, Ko, Young Hyeh, Manni, Martina, Skrypets, Tetiana, Horwitz, Steven M., De Souza, Carmino Antonio, Radford, John A., Bobillo, Sabela, Prates, Maria Virginia, Ferreri, Andrés J.M., Chiattone, Carlos, Spina, Michele, Vose, Julie M., Chiappella, Annalisa, Laszlo, Daniele, Marino, Dario, Stelitano, Caterina, and Federico, Massimo

Published
2021
Full Text
View/download PDF

17. Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics

Author

Torka, Pallawi, Kothari, Shalin K., Sundaram, Suchitra, Li, Shaoying, Medeiros, L. Jeffrey, Ayers, Emily C., Landsburg, Daniel J., Bond, David A., Maddocks, Kami J., Giri, Anshu, Hess, Brian, Pham, Luu Q., Advani, Ranjana, Liu, Yang, Barta, Stefan Klaus, Vose, Julie M., Churnetski, Michael C., Cohen, Jonathon B., Burkart, Madelyn, Karmali, Reem, Zurko, Joanna, Mehta, Amitkumar, Olszewski, Adam J., Lee, Sarah, Hill, Brian T., Burns, Timothy F., Lansigan, Frederick, Rabinovich, Emma, Peace, David, Groman, Adrienne, Attwood, Kristopher, and Hernandez-Ilizaliturri, Francisco J.

Published
2020
Full Text
View/download PDF

18. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma

Author

Takahashi, Koichi, Sivina, Mariela, Hoellenriegel, Julia, Oki, Yasuhiro, Hagemeister, Fredrick B, Fayad, Luis, Romaguera, Jorge E, Fowler, Nathan, Fanale, Michelle A, Kwak, Larry W, Samaniego, Felipe, Neelapu, Sattva, Xiao, Lianchun, Huang, Xuelin, Kantarjian, Hagop, Keating, Michael J, Wierda, William, Fu, Kai, Chan, Wing C, Vose, Julie M, O'Brien, Susan, Davis, Richard E, and Burger, Jan A

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Cancer, Rare Diseases, Lymphoma, Hematology, Clinical Research, Aetiology, 2.1 Biological and endogenous factors, Adenine, Antineoplastic Agents, B-Cell Activation Factor Receptor, Biomarkers, Tumor, Cell Line, Tumor, Chemokine CCL3, Chemokine CCL4, Enzyme-Linked Immunosorbent Assay, Epidemiologic Methods, Humans, Lymphoma, Large B-Cell, Diffuse, Piperidines, Prognosis, Pyrazoles, Pyrimidines, Signal Transduction, chemokines, diffuse large B-cell lymphoma, lymphoma, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

B cell receptor (BCR) signalling is an important pathway in diffuse large B cell lymphoma (DLBCL). In response to BCR triggering, normal and malignant B cells secrete the chemokines CCL3 and CCL4 to attract accessory cells to the tissue microenvironment. We measured CCL3 and CCL4 serum concentrations in 102 patients with newly diagnosed DLBCL by enzyme-linked immunosorbent assay, investigated their prognostic impact and validated our findings in an independent cohort of 51 patient samples. We also tested CCL3 and CCL4 secretion by DLBCL cells, and the influence of BTK inhibitors on the secretion of these chemokines. High CCL3 (≥40 pg/ml) serum concentrations correlated with higher international prognostic index, lactate dehydrogenase and β2 microglobulin, as did CCL4 (≥180 pg/ml) with advanced Ann Arbor stages. High CCL3 levels correlated with significantly shorter progression-free and overall survival. The in vitro studies demonstrated that activated B cell-like, but not germinal centre B cell-like DLBCL cells, secrete high levels of CCL3 and CCL4 after BCR triggering, which was exquisitely sensitive to BCR pathway inhibition. These findings support CCL3 and CCL4 protein concentrations as biomarkers for BCR pathway activation and prognosis in DLBCL.

Published
2015

20. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.

Author

Zelenetz, Andrew D, Gordon, Leo I, Wierda, William G, Abramson, Jeremy S, Advani, Ranjana H, Andreadis, C Babis, Bartlett, Nancy, Byrd, John C, Czuczman, Myron S, Fayad, Luis E, Fisher, Richard I, Glenn, Martha J, Habermann, Thomas M, Harris, Nancy Lee, Hoppe, Richard T, Horwitz, Steven M, Kelsey, Christopher R, Kim, Youn H, Krivacic, Susan, LaCasce, Ann S, Nademanee, Auayporn, Porcu, Pierluigi, Press, Oliver, Rabinovitch, Rachel, Reddy, Nishitha, Reid, Erin, Saad, Ayman A, Sokol, Lubomir, Swinnen, Lode J, Tsien, Christina, Vose, Julie M, Wilson, Lynn, Yahalom, Joachim, Zafar, Nadeem, Dwyer, Mary, and Sundar, Hema

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Orphan Drug, Hematology, Clinical Research, Rare Diseases, Lymphoma, Cancer, Algorithms, Comorbidity, Disease Management, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm Staging, Prognosis, National comprehension cancer network, Oncology & Carcinogenesis, Oncology and carcinogenesis, Health services and systems
Abstract

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease, which are managed in the same way. The advent of novel monoclonal antibodies (ofatumumab and obinutuzumab) led to the development of effective chemoimmunotherapy regimens. The recently approved small molecule kinase inhibitors (ibrutinib and idelalisib) are effective treatment options for CLL in elderly patients with decreased tolerance for aggressive regimens and in patients with poor prognostic features who do not benefit from conventional chemoimmunotherapy regimens. This portion of the NCCN Guidelines for Non-Hodgkin's Lymphomas describes the recent specific to the incorporation of recently approved targeted therapies for the management of patients with newly diagnosed and relapsed or refractory CLL/SLL.

Published
2015

21. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial

Author

Nastoupil, Loretta J, Lunning, Matthew A, Vose, Julie M, Schreeder, Marshall T, Siddiqi, Tanya, Flowers, Christopher R, Cohen, Jonathon B, Burger, Jan A, Wierda, William G, O'Brien, Susan, Sportelli, Peter, Miskin, Hari P, Purdom, Michelle A, Weiss, Michael S, and Fowler, Nathan H

Published
2019
Full Text
View/download PDF

23. Non-Hodgkin's lymphomas, version 4.2014.

Author

Zelenetz, Andrew D, Gordon, Leo I, Wierda, William G, Abramson, Jeremy S, Advani, Ranjana H, Andreadis, C Babis, Bartlett, Nancy, Byrd, John C, Czuczman, Myron S, Fayad, Luis E, Fisher, Richard I, Glenn, Martha J, Harris, Nancy Lee, Hoppe, Richard T, Horwitz, Steven M, Kelsey, Christopher R, Kim, Youn H, Krivacic, Susan, LaCasce, Ann S, Nademanee, Auayporn, Porcu, Pierluigi, Press, Oliver, Rabinovitch, Rachel, Reddy, Nishitha, Reid, Erin, Saad, Ayman A, Sokol, Lubomir, Swinnen, Lode J, Tsien, Christina, Vose, Julie M, Yahalom, Joachim, Zafar, Nadeem, Dwyer, Mary, and Sundar, Hema

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Cancer, Hematology, Rare Diseases, Stem Cell Research, Lymphoma, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, Humans, Lymphoma, Non-Hodgkin, Neoplasm Staging, Recurrence, National comprehensive cancer network, Oncology & Carcinogenesis, Oncology and carcinogenesis, Health services and systems
Abstract

Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Mantle cell lymphoma (MCL) accounts for approximately 6% of all newly diagnosed NHL cases. Radiation therapy with or without systemic therapy is a reasonable approach for the few patients who present with early-stage disease. Rituximab-based chemoimmunotherapy followed by high-dose therapy and autologous stem cell rescue (HDT/ASCR) is recommended for patients presenting with advanced-stage disease. Induction therapy followed by rituximab maintenance may provide extended disease control for those who are not candidates for HDT/ASCR. Ibrutinib, a Bruton tyrosine kinase inhibitor, was recently approved for the treatment of relapsed or refractory disease. This manuscript discusses the recommendations outlined in the NCCN Guidelines for NHL regarding the diagnosis and management of patients with MCL.

Published
2014

33. Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II–IV peripheral T‐cell lymphoma.

Author

Stuver, Robert, Horwitz, Steven M., Advani, Ranjana H., Vose, Julie M., Lee, Hun Ju, Mehta‐Shah, Neha, Zain, Jasmine M., Haverkos, Bradley, Lechowicz, Mary Jo, Moskowitz, Alison J., Pham, Luu Q., Leyden, Elizabeth, Ansell, Stephen M., and Lunning, Matthew A.

Subjects
T-cell lymphoma, LENALIDOMIDE, FEBRILE neutropenia, PROGRESSION-free survival, STEM cell treatment
Abstract

Summary: There remains no one standard induction for nodal‐based peripheral T‐cell lymphoma (PTCL). We conducted a phase II study of lenalidomide plus CHOEP as a novel induction strategy. Patients received CHOEP at standard doses in combination with 10 mg of lenalidomide on days 1–10 of a 21‐day cycle for six cycles of therapy followed by observation, high‐dose therapy with autologous stem cell rescue, or maintenance lenalidomide per provider preference. Among 39 patients evaluable for efficacy, the objective response rate after six cycles was 69%, with complete response in 49%, partial response in 21%, stable disease in 0% and progressive disease in 13%. Thirty‐two patients (82%) completed full induction, and seven patients (18%) discontinued for toxicity, primarily hematologic. Any grade hematologic toxicity occurred in over 50% of patients, with grade 3 or 4 febrile neutropenia occurring in 35% of patients despite mandated growth factors. With a median followup of surviving patients of 21.3 months, the estimated 2‐year progression‐free and overall survival were 55% (95% CI 37%–70%) and 78% (95% CI 59%–89%), respectively. In sum, six cycles of lenalidomide plus CHOEP resulted in a modest response rate primarily due to hematologic toxicity, which prevented all patients from completing planned induction. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

34. Lenalidomide maintenance following high‐dose therapy and autologous haematopoietic stem cell transplantation in chemo‐resistant or high‐risk non‐Hodgkin lymphoma: A phase I/II study.

Author

Vose, Julie M., Ganguly, Siddhartha, Bierman, Philip J., Bociek, R. Gregory, Lunning, Matthew, Lyden, Liz, Meza, Jane L., Caimi, Paolo F., and Armitage, James O.

Subjects
*HEMATOPOIETIC stem cell transplantation, *NON-Hodgkin's lymphoma, *DIFFUSE large B-cell lymphomas, *LENALIDOMIDE, *MANTLE cell lymphoma
Abstract

Summary: Improved maintenance treatments are needed for patients with relapsed/refractory aggressive lymphomas after autologous haematopoietic stem cell transplantation (ASCT). Several studies with lenalidomide have been found to have activity in the treatment of relapsed/refractory aggressive lymphomas. In the present phase I/II, single‐arm, open‐label study, 59 patients with high‐risk relapsed non‐Hodgkin lymphoma received pretransplant BEAM chemotherapy and ASCT followed by 12 months of maintenance lenalidomide once daily on Days 1–21 (28‐day cycles) beginning at post‐transplantation Day 100. The most common histologies were mantle cell lymphoma (56%) and diffuse large B‐cell lymphoma (24%). The maximum tolerated dose in the dose‐finding part of the study was 15 mg, but cytopenias led to the subsequent adoption of a 10 mg dose in the final study. Sixteen patients (27%) completed 12 cycles of lenalidomide maintenance. The most common reason for discontinuation was adverse events (31%). These were primarily haematologic, and 56% of patients experienced Grade 3–4 events. Two‐year PFS rates (95% CIs) were 70% (56%–80%), 45% (19%–68%) and 81% (66%–90%); 2‐year OS rates (95% CIs) were 91% (80%–96%), 93% (61%–99%) and 90% (76%–96%) in all patients, patients completing and patients not completing 12‐month maintenance respectively. These results do not support the use of lenalidomide maintenance in this setting. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

35. ASCO Policy Statement on Biosimilar and Interchangeable Products in Oncology.

Author

Rodriguez, Gladys, Mancuso, Joan, Lyman, Gary H., Cardoso, Fatima, Nahleh, Zeina, Vose, Julie M., Gralow, Julie R., Francisco, Michael, and Sherwood, Shimere

Subjects
DRUG approval, PHARMACOLOGY, NEGOTIATION, BIOSIMILARS, MEDICAL care costs, MEDICAL care, COST benefit analysis, PHARMACEUTICAL services insurance, DECISION making, BUSINESS, DRUG monitoring, MANAGEMENT, PATIENT education, TUMORS, COMMITMENT (Psychology), MISINFORMATION, CANCER patient medical care, PATIENT safety
Abstract

As the voice of cancer care clinicians and the patients they serve, ASCO has taken steps to elevate awareness about biosimilar products and their use in oncology. In 2018, ASCO released its Statement on Biosimilars in Oncology which was subsequently published in the Journal of Clinical Oncology to serve as an educational tool which highlighted and provided guidance on several topical areas surrounding biosimilars. At the time of its publication, the US Food and Drug Administration (FDA) had approved eight biosimilar products for use in the United States, including one product for use as a supportive care agent in the cancer setting and two products for use in the treatment for cancer. This number has risen dramatically (40 approvals), with a total of 22 cancer or cancer-related biosimilar products approved since 2015. Recently, the FDA also approved the four interchangeable biosimilar products for diabetes, certain inflammatory diseases, and certain ophthalmic diseases. Given the current market dynamics and the regulatory landscape, this ASCO manuscript now seeks to propose several policy recommendations across the scope of value, interchangeability, clinician barriers, and patient education and access. This policy statement is intended to guide ASCO's future activities and strategies and serves to affirm our commitment to providing education to the oncology community on the use of biosimilars in the cancer setting. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

37. Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation

Author

Perales, Miguel-Angel, Ceberio, Izaskun, Armand, Philippe, Burns, Linda J., Chen, Robert, Cole, Peter D., Evens, Andrew M., Laport, Ginna G., Moskowitz, Craig H., Popat, Uday, Reddy, Nishitha M., Shea, Thomas C., Vose, Julie M., Schriber, Jeffrey, Savani, Bipin N., and Carpenter, Paul A.

Published
2015
Full Text
View/download PDF

39. Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma

Author

Iqbal, Javeed, Shen, Yulei, Huang, Xin, Liu, Yanyan, Wake, Laura, Liu, Cuiling, Deffenbacher, Karen, Lachel, Cynthia M., Wang, Chao, Rohr, Joseph, Guo, Shuangping, Smith, Lynette M., Wright, George, Bhagavathi, Sharathkumar, Dybkaer, Karen, Fu, Kai, Greiner, Timothy C., Vose, Julie M., Jaffe, Elaine, Rimsza, Lisa, Rosenwald, Andreas, Ott, German, Delabie, Jan, Campo, Elias, Braziel, Rita M., Cook, James R., Tubbs, Raymond R., Armitage, James O., Weisenburger, Dennis D., Staudt, Louis M., Gascoyne, Randy D., McKeithan, Timothy W., and Chan, Wing C.

Published
2015
Full Text
View/download PDF

40. Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation

Author

Hamadani, Mehdi, Hari, Parameswaran N., Zhang, Ying, Carreras, Jeanette, Akpek, Görgün, Aljurf, Mahmoud D., Ayala, Ernesto, Bachanova, Veronika, Chen, Andy I., Chen, Yi-Bin, Costa, Luciano J., Fenske, Timothy S., Freytes, César O., Ganguly, Siddhartha, Hertzberg, Mark S., Holmberg, Leona A., Inwards, David J., Kamble, Rammurti T., Kanfer, Edward J., Lazarus, Hillard M., Marks, David I., Nishihori, Taiga, Olsson, Richard, Reddy, Nishitha M., Rizzieri, David A., Savani, Bipin N., Solh, Melhem, Vose, Julie M., Wirk, Baldeep, Maloney, David G., Smith, Sonali M., Montoto, Silvia, and Saber, Wael

Published
2014
Full Text
View/download PDF

42. Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma

Author

Wirk, Baldeep, Fenske, Timothy S., Hamadani, Mehdi, Zhang, Mei-Jie, Hu, Zhen-Huan, Akpek, Görgün, Aljurf, Mahmoud D., Armand, Philippe, Ayala, Ernesto, Bachanova, Veronika, Bolwell, Brian, Cairo, Mitchell S., Cashen, Amanda, Chen, Yi-Bin, Costa, Luciano J., Farhan, Shatha, Freytes, César O., Gajewski, James L., Gibson, John, Hale, Gregory A., Holmberg, Leona A., Hsu, Jack W., Inwards, David J., Kamble, Rummurti T., Maharaj, Dipnarine, Maziarz, Richard T., Munker, Reinhold, Nath, Rajneesh, Reddy, Nishitha M., Reeder, Craig B., Rizzieri, David A., Sauter, Craig S., Savani, Bipin N., Schouten, Harry C., Sureda, Anna, Vose, Julie M., Waller, Edmund K., Wiernik, Peter H., Gale, Robert Peter, Burns, Linda J., and Saber, Wael

Published
2014
Full Text
View/download PDF

44. ABCL-191 Extended Follow-Up Beyond 2.5 Years Demonstrates Long-Term Efficacy in Complete Responders Following Epcoritamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)

Author

Karimi, Yasmin H., Thieblemont, Catherine, Ghesquieres, Herve, Cheah, Chan Y., Roost Clausen, Michael, Cunningham, David, Jurczak, Wojciech, Linton, Kim M., Hutchings, Martin, Phillips, Tycel, Farooq, Umar, Seog Kim, Won, Dinh, Minh H., Ghosh, Jagannath, Pallai, Rajash, Wielgos-Bonvallet, Monica, Eskelund, Christian, Lugtenburg, Pieternella J., and Vose, Julie M.

Published
2024
Full Text
View/download PDF

45. Extended Follow-Up Beyond 2 .5 Years Demonstrates Long-Term Efficacy in Complete Responders Following Epcoritamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)

Author

Karimi, Yasmin H., Thieblemont, Catherine, Ghesquieres, Herve, Cheah, Chan Y., Roost Clausen, Michael, Cunningham, David, Jurczak, Wojciech, Linton, Kim M., Hutchings, Martin, Phillips, Tycel, Farooq, Umar, Seog Kim, Won, Dinh, Minh H., Ghosh, Jagannath, Pallai, Rajash, Wielgos-Bonvallet, Monica, Eskelund, Christian, Lugtenburg, Pieternella J., and Vose, Julie M.

Published
2024
Full Text
View/download PDF

46. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.

Author

Wang, Yucai, Jain, Preetesh, Locke, Frederick L., Maurer, Matthew J., Frank, Matthew J., Munoz, Javier L., Dahiya, Saurabh, Beitinjaneh, Amer M., Jacobs, Miriam T., Mcguirk, Joseph P., Vose, Julie M., Goy, Andre, Andreadis, Charalambos, Hill, Brian T., Dorritie, Kathleen A., Oluwole, Olalekan O., Deol, Abhinav, Paludo, Jonas, Shah, Bijal, and Wang, Trent

Published
2023
Full Text
View/download PDF

47. Genomic profiling for clinical decision making in lymphoid neoplasms

Author

de Leval, Laurence, Alizadeh, Ash A., Bergsagel, P. Leif, Campo, Elias, Davies, Andrew, Dogan, Ahmet, Fitzgibbon, Jude, Horwitz, Steven M., Melnick, Ari M., Morice, William G., Morin, Ryan D., Nadel, Bertrand, Pileri, Stefano A., Rosenquist, Richard, Rossi, Davide, Salaverria, Itziar, Steidl, Christian, Treon, Steven P., Zelenetz, Andrew D., Advani, Ranjana H., Allen, Carl E., Ansell, Stephen M., Chan, Wing C., Cook, James R., Cook, Lucy B., d’Amore, Francesco, Dirnhofer, Stefan, Dreyling, Martin, Dunleavy, Kieron, Feldman, Andrew L., Fend, Falko, Gaulard, Philippe, Ghia, Paolo, Gribben, John G., Hermine, Olivier, Hodson, Daniel J., Hsi, Eric D., Inghirami, Giorgio, Jaffe, Elaine S., Karube, Kennosuke, Kataoka, Keisuke, Klapper, Wolfram, Kim, Won Seog, King, Rebecca L., Ko, Young H., LaCasce, Ann S., Lenz, Georg, Martin-Subero, José I., Piris, Miguel A., Pittaluga, Stefania, Pasqualucci, Laura, Quintanilla-Martinez, Leticia, Rodig, Scott J., Rosenwald, Andreas, Salles, Gilles A., San-Miguel, Jesus, Savage, Kerry J., Sehn, Laurie H., Semenzato, Gianpietro, Staudt, Louis M., Swerdlow, Steven H., Tam, Constantine S., Trotman, Judith, Vose, Julie M., Weigert, Oliver, Wilson, Wyndham H., Winter, Jane N., Wu, Catherine J., Zinzani, Pier L., Zucca, Emanuele, Bagg, Adam, and Scott, David W.

Published
2022
Full Text
View/download PDF

48. Specific Clonal Mutations Are Predictive of Therapy-Related Myeloid Neoplasms (tMN) after Autologous Peripheral Blood Stem Cell Transplantation (aPBSCT) for Lymphoma

Author

Bhatia, Smita, Yan, Chengcheng, Richard, Melissa A, He, Jianbo, Bosworth, Alysia, Crossman, David, Singh, Purnima, Hageman, Lindsey, Armenian, Saro H., Vose, Julie M., Weisdorf, Daniel J., Yasui, Yutaka, Ebert, Benjamin L., Gibson, Christopher J., Forman, Stephen J, and Bhatia, Ravi

Published
2022
Full Text
View/download PDF

50. High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series

Author

Epperla, Narendranath, Zayac, Adam, Landsburg, Daniel J., Hughes, Mitchell, Bock, Allison M., Nowakowski, Grzegorz S., Ayers, Emily C., Girton, Mark, Hu, Marie, Beckman, Amy, Li, Shaoying, Medeiros, L. Jeffrey, Chang, Julie E., Stepanovic, Adam, Kurt, Habibe, Sandoval-Sus, Jose, Ansari-Lari, M. Ali, Kothari, Shalin K., Kress, Anna, Xu, Mina L, Torka, Pallawi, Sundaram, Suchitra, Smith, Stephen D, Naresh, Kikkeri N, Karimi, Yasmin, Bond, David A., Farooq, Umar, Saad, Mahak, Evens, Andrew Matthew, Pandya, Karan, Naik, Seema G, Kamdar, Manali, Haverkos, Bradley M., Karmali, Reem, Oh, Timothy S, Vose, Julie M., Nutsch, Heather, Rubinstein, Paul, Chaudhry, Amina, and Olszewski, Adam J.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results